<List><item><source>MED</source><extId>20698721</extId><pmcid>3586090</pmcid><annotations><annotation><prefix>abel phase I trial (</prefix><exact>NCT00880854</exact><postfix>) of tremelimumab in</postfix><tags><tag><name>NCT00880854</name><uri>http://identifiers.org/clinicaltrials/NCT00880854</uri></tag></tags><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider></annotation><annotation><prefix>d a phase II trial (</prefix><exact>NCT00313794</exact><postfix>) evaluating tremeli</postfix><tags><tag><name>NCT00313794</name><uri>http://identifiers.org/clinicaltrials/NCT00313794</uri></tag></tags><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider></annotation><annotation><prefix>d a phase II trial (</prefix><exact>NCT01008358</exact><postfix>) of tremelimumab in</postfix><tags><tag><name>NCT01008358</name><uri>http://identifiers.org/clinicaltrials/NCT01008358</uri></tag></tags><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider></annotation><annotation><prefix>g a phase II trial (</prefix><exact>NCT00610857</exact><postfix>) of tremelimumab in</postfix><tags><tag><name>NCT00610857</name><uri>http://identifiers.org/clinicaltrials/NCT00610857</uri></tag></tags><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider></annotation><annotation><prefix>g a phase II trial (</prefix><exact>NCT00471887</exact><postfix>) of tremelimumab in</postfix><tags><tag><name>NCT00471887</name><uri>http://identifiers.org/clinicaltrials/NCT00471887</uri></tag></tags><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider></annotation><annotation><prefix>abel phase I trial (</prefix><exact>NCT00556023</exact><postfix>) is underway in Can</postfix><tags><tag><name>NCT00556023</name><uri>http://identifiers.org/clinicaltrials/NCT00556023</uri></tag></tags><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider></annotation><annotation><prefix>e-escalation trial (</prefix><exact>NCT00702923</exact><postfix>) is underway in the</postfix><tags><tag><name>NCT00702923</name><uri>http://identifiers.org/clinicaltrials/NCT00702923</uri></tag></tags><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider></annotation><annotation><prefix>A phase I trial (</prefix><exact>NCT00372853</exact><postfix>) is underway to determ</postfix><tags><tag><name>NCT00372853</name><uri>http://identifiers.org/clinicaltrials/NCT00372853</uri></tag></tags><type>Accession Numbers</type><section>Introduction (http://purl.org/orb/Introduction)</section><provider>Europe PMC</provider></annotation><annotation><prefix>m a phase II trial (</prefix><exact>NCT00312975</exact><postfix>; n = 87), the incid</postfix><tags><tag><name>NCT00312975</name><uri>http://identifiers.org/clinicaltrials/NCT00312975</uri></tag></tags><type>Accession Numbers</type><section>Conclusion (http://purl.obolibrary.org/obo/IAO_0000615)</section><provider>Europe PMC</provider></annotation></annotations></item></List>